Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
暂无分享,去创建一个
Marc Peeters | Bart Neyns | E. Van Cutsem | B. Neyns | J. Canon | Y. Humblet | J. Maurel | M. Peeters | S. Siena | R. Amado | M. Wolf | J. Van Laethem | Eric Van Cutsem | Salvatore Siena | Alain Hendlisz | Yves Humblet | Jean-Luc Canon | Michael Wolf | A. Hendlisz | Jean-Luc Van Laethem | Rafael G Amado | Gary Richardson | G. Richardson | Joan Maurel
[1] Ron Brookmeyer,et al. A Confidence Interval for the Median Survival Time , 1982 .
[2] Mark Levine,et al. Radiation therapy and tamoxifen: concurrent or sequential? That is the question. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[4] J. Hainsworth,et al. A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma , 1999, Cancer.
[5] C. Davis,et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. , 1999, Cancer research.
[6] J. Berlin,et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) , 2005 .
[7] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[9] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[11] J. Lotz,et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.
[12] E. Van Cutsem,et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[14] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[15] R. Figlin,et al. Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies , 2005 .
[16] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[17] J. Berlin,et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Perez-soler,et al. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[21] J. Hecht,et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Figlin,et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Figlin,et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. , 2004, International journal of radiation oncology, biology, physics.
[25] P. Catalano,et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 , 2005 .
[26] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[27] L. Ploughman,et al. Preclinical discovery and clinical validation of predictive markers of response to cetuximab (Erbitux™) in metastatic colorectal cancer , 2006 .
[28] Louis M Weiner,et al. Fully Human Therapeutic Monoclonal Antibodies , 2006, Journal of immunotherapy.
[29] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[30] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[31] J. Hecht,et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] W. Scheithauer,et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.